Predicting Phase III clinical trials immediately post-discovery with 99.94% proven accuracy, using virtual cells, organs, and patients.

Our proprietary Phase Advance Predictive Technology Platform™ powers complex mathematical models of disease progression in silico to accurately predict day-to-day responses at individual patient levels in future phase III trials. These in silico clinical trials predict precise endpoints today, even for drugs that have never entered a single animal or patient.

How Phase Advance helps

3 months per 10 molecules to deliver predictions

See the future, just post discovery.

With a known mechanism of action and binding affinities, Phase Advance PTP™ can deliver all the insights of a full Phase III clinical trial FDA-grade case report form.

Plan your portfolio with advance knowledge.

Select assets for investment with unparalleled insights into their future performance against placebo, standard of care, and competitor therapies.

Design clinical trials with predictive insights.

Know the best trial biomarkers, clinical endpoints, sampling strategy, and sample size based on optimal sampling theory. We incorporate diversity and expected outcomes in different genetic groups, to identify best population to recruit.

97% of drug candidates will fail after spending ~$1.3 billion per drug

Most new pharmaceuticals will fail after discovery, during preclinical testing, or much later after years of work and billions of invested dollars. Failure is apparent only after spending up to $2B in clinical trials, 12-15 years later. Only 1 in 6,000 molecules drive Return On Investment.

Phase Advance accurately predicts success or failure to save $2B and up to 14 years in costs

Phase Advance AI is AI.

Phase Advance’s nonlinear mathematical models of disease progression are the core of our advancement, and our AI has been custom-built over decades to accelerate our predictions. We started with science, modeling human biology in its natural, nonlinear functions, and utilized AI not to extrapolate how the human body works, but to seek patterns within individual day-to-day patient response to drugs.

Phase Advance can forecast Phase III clinical trial results at the discovery phase:

We quantitatively map out the entire drug development process (preclinical and clinical) by first predicting the individual-patient level clinical response rates, best biomarkers, optimal doses, and how well each drug will perform versus other candidate drugs, before the preclinical stage.

Optimal dose
Optimal drugs combos
Clinical trial endpoints before & after preclinical development
Clinical trial design
Novel biomarkers

Ethnic/genetic population-based predictions of efficacy & toxicity rates
Lifetime model for optimal treatment start
Predicted efficacy versus market leader
Parameters to optimize in molecules

Our Clients

CRO

Optimized clinical trial design
Ability to pre-test genetically diverse populations
Reduce recruitment necessary
Lower risk for volunteers

BioPHARMA

Rank which molecules to move forward
Optimize leads to change winners to losers
Predict performance vs standard of care
Ethical placebo arms for rare disease drugs

Investors

Identify which molecules to invest in
Assist in due diligence
Predict performance vs competitors

AI DISCOVERY

Predict performance
Rank and de-risk discovered molecules
Optimize predicted poor performers

Contact Us

Let us know how we can help you.